Synthgene key facts
- Manufacturer of life sciences raw materials designed to support research and development in biotechnology and molecular medicine.
- It has raised $46.8M; the latest was Later Stage VC in Mar 2026.
- Notable investors include Legend Star, YuanBio Venture Capital, Leader Venture Capital, Granite Asia, GSR United Capital — 14 tracked in total.
- Status: Privately Held (backing).
Who backs Synthgene
14+- ·The complete investor list: 14 names
- ·Watch Synthgene: the Monday email on marks, rounds and moves
Synthgene funding rounds
No funding rounds for Synthgene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Synthgene investors
14 investors are on record for Synthgene, including Legend Star, YuanBio Venture Capital, Leader Venture Capital and Granite Asia. By type, the record holds 4 venture capital firms and 1 hedge fund.
About Synthgene
Manufacturer of life sciences raw materials designed to support research and development in biotechnology and molecular medicine. The company offers nucleic acid drug materials, cell and gene therapy inputs, immunodiagnostic materials, and mRNA-related reagents supported by advanced platforms such as antibody discovery and enzyme evolution, enabling biotechnology companies, research institutions, and diagnostic developers to accelerate therapeutic development and improve research efficiency.
- Sector
- Healthcare
- HQ
- Wuxi, China
- Founded
- 2018
- Employees
- 22
- Website
- syngenebio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Synthgene doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.